The full repayment of the Sanofi Development Balance removes a drag on collaboration profits starting Q3, providing a structural tailwind to earnings. With double-digit top- and bottom-line growth, raised gross margin guidance, and a $2.5B buyback authorization, the stock should re-rate higher. Key catalysts to watch: cemdisiran PDUFA in November 2026 and Dupixent CSU expansion in pediatrics.
Drugs in focus
REGN drug pipeline →Otarmeni
● Neutral Named in this 8-K- Impact
- Phase
- Approved (accelerated approval)
- Time to market
- Already FDA-approved (April 23, 2026); commercially available in the U.S.
- Next catalyst
- BLA filing · 2026
What to watchOtarmeni's approval binary has passed and the drug is provided free in the U.S. under a government pricing deal, so it generates zero direct revenue. For Regeneron investors, EMA approval (under accelerated assessment review) is a modest upside tailwind but immaterial given the ultra-rare indication and free-access model. The stock's bigger catalysts are Eylea HD dosing expansions, the garetosmab PDUFA (August 2026), and Dupixent pipeline growth, not this drug.
- ▲ Cemdisiran 6/10 Filed/PDUFA (Phase 3 NIMBLE complete; NDA under FDA Priority Review) Named in filing
- ▲ Dupixent 4/10 Approved (marketed since 2017; additional Phase 3 trials ongoing for label expansion) Named in filing
- ● Evkeeza 4/10 Approved Named in filing
- ● EYLEA HD 4/10 Approved Named in filing
- ● Libtayo 4/10 Approved Named in filing
- 11 more · All REGN drugs, catalysts & trials →
Price Chart
Executive Summary
Regeneron reported Q2 2026 revenue of $4.29B (+17% YoY) and non-GAAP EPS of $14.29, a 40.1% beat vs consensus of $10.20, driven by Dupixent (+38%), EYLEA HD (+52%), and Libtayo (+30%). Guidance was modestly tightened higher on R&D and gross margins, and the Sanofi Development Balance was fully repaid, which will boost collaboration profits starting Q3. The strong beat and raised fundamentals support a bullish read, though GAAP net income declined 7% due to a $127M IPR&D charge and higher tax rate.
Key Financial Metrics
Key Facts
- Total revenues $4.29B, +17% YoY vs $3.68B
- Non-GAAP EPS $14.29, +11% YoY, 40.1% above $10.20 consensus
- Dupixent global net sales $6.0B, +38% YoY (record)
- EYLEA HD U.S. net sales $596M, +52% YoY (record)
- Libtayo global net sales $489M, +30% YoY (record)
- Sanofi collaboration revenue $2.17B, +51% YoY; Development Balance fully repaid
- GAAP net income $1.30B, -7% YoY due to $127M IPR&D charge and higher tax rate
- 2026 guidance: GAAP R&D narrowed to $6.50-6.635B; non-GAAP gross margin raised to 84-85%
- Share repurchases of $1.2B in Q2, $2.0B YTD; $2.5B remaining
- Cemdisiran NDA accepted for priority review in gMG, PDUFA Nov 2026
Financial Impact
Non-GAAP EPS beat consensus by $4.09 (40.1%); revenue beat by $460M (12.0%)
Risk Factors
- Fianlimab Phase 3 melanoma trial missed primary endpoint (PFS vs pembrolizumab)
- EYLEA franchise U.S. sales declined 12% YoY as patients transition to EYLEA HD at lower net price
- GAAP net income declined 7% YoY due to $127M IPR&D charge and higher effective tax rate (15.1% vs 8.4%)
- Patent litigation related to EYLEA remains an overhang
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0000872589-26-000023 |
| Document: 0000872589-26-000023-index-headers.html | 0000872589-26-000023 |
| Document: 0000872589-26-000023-index.html | 0000872589-26-000023 |
| Document: 0000872589-26-000023.txt | 0000872589-26-000023 |
| 8-K Data (Synthetic) | 0000872589-26-000023 |
Track record
53 reports on REGN
11 of 17 bullish or bearish reports moved the stock their way by T+20. Best: +31.76% at T+20 after the Oct 6, 2026 report. 17 of 21 went positive at some point.
Filters
- Nov 16, 2026today 144 Neutral 2/10 Entry $951.23 Now $952.40 +0.12% settles Dec 16
- Nov 16, 2026today 144 Neutral 2/10 Entry $948.00 Now $952.40 +0.46% settles Dec 16
- Nov 12, 20264d ago Press Release Bullish 5/10 Entry $955.47 Now $952.40 −0.32% settles Dec 14
- Nov 5, 202611d ago Insider Cluster Neutral 2/10 Entry $904.35 Now $952.40 +5.31% settles Dec 7
- Nov 5, 202611d ago Insider Cluster Neutral 3/10 Entry $904.35 Now $952.40 +5.31% settles Dec 7
- Nov 4, 202612d ago 144 Neutral 1/10 Entry $902.90 Now $952.40 +5.48% settles Dec 4
- Nov 4, 202612d ago 144 Neutral 2/10 Entry $902.90 Now $952.40 +5.48% settles Dec 4
- Nov 3, 202613d ago Insider Cluster Neutral 2/10 Entry $930.67 Now $952.40 +2.33% settles Dec 3
- Nov 3, 202613d ago 144 Neutral 2/10 Entry $930.67 Now $952.40 +2.33% settles Dec 3
- Nov 3, 202613d ago Insider Cluster Neutral 2/10 Entry $930.67 Now $952.40 +2.33% settles Dec 3
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers